硝苯地平控释片联合福辛普利钠片治疗糖尿病合并高血压的临床效果分析  

Clinical effect analysis of nifedipine controlled release tablets combined with fosinopril sodium tablets in the treatment of diabetes mellitus complicated with hypertension

作　　者：刘佩虹 LIU Pei-hong(Baijiao Town Health Center of Doumen District,Zhuhai 519000,China)

机构地区：[1]广东省珠海市斗门区白蕉镇卫生院,519000

出　　处：《中国现代药物应用》2024年第3期38-42,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析糖尿病合并高血压患者采用硝苯地平控释片以及福辛普利钠片联合治疗的临床效果。方法抽选100例糖尿病合并高血压患者资料开展研究,依照随机数字法分为观察组以及对照组,每组50例。对照组患者仅服用硝苯地平控释片治疗,观察组患者采用硝苯地平控释片以及福辛普利钠片联合治疗。对比两组患者治疗前后的收缩压(SBP)、舒张压(DBP),肾功能指标[胱抑素C(CysC)、同型半胱氨酸(Hcy)、尿白蛋白排泄率(UAER)、尿微量白蛋白(mALB)]及血栓调节蛋白(TM)、血管性血友病因子(vWF)、转化生长因子β1(TGF-β1)水平,不良反应发生情况。结果治疗后,两组患者的SBP、DBP水平显著低于治疗前,且观察组患者的SBP(135.43±6.43)mm Hg(1 mm Hg=0.133 kPa)、DBP(87.87±3.30)mm Hg显著低于对照组的(137.54±2.91)、(96.76±2.65)mm Hg(P<0.05)。治疗后,两组患者的CysC、Hcy、UAER、mALB水平均显著低于治疗前,且观察组患者的CysC(0.31±0.63)mg/L、Hcy(6.14±0.34)μmol/L、UAER(115.73±7.57)μg/min、mALB(24.25±1.43)mg/L均显著低于对照组的(0.76±0.02)mg/L、(11.31±0.58)μmol/L、(127.38±5.49)μg/min、(35.36±0.81)mg/L(P<0.05)。治疗后,两组TM、vWF、TGF-β1水平均显著低于治疗前,且观察组TM(27.32±0.99)mg/L、vWF(115.37±6.11)%、TGF-β1(111.27±5.37)mg/ml均显著低于对照组的(39.43±1.26)mg/L、(132.43±5.39)%、(132.36±5.31)mg/ml(P<0.05)。治疗后观察组不良反应发生率与对照组不存在明显差异(P>0.05)。结论临床上针对糖尿病合并高血压患者采用硝苯地平控释片以及福辛普利钠片联合治疗具有显著的疗效,用药后患者的高血压以及糖尿病症状显著改善,且未发生显著的不良反应,值得推广。Objective To analyze the clinical effect of nifedipine controlled release tablets combined with fosinopril sodium tablets in the treatment of diabetes mellitus complicated with hypertension.Methods 100 diabetes mellitus patients with hypertension were randomly divided into an observation group and a control group,with 50 cases in each group.The control group was treated with nifedipine controlled release tablets,and the observation group was treated with nifedipine controlled release tablets and fosinopril sodium tablets.Comparison was made on systolic blood pressure(SBP),diastolic blood pressure(DBP),renal function indicators[cystatin C(CysC),homocysteine(Hcy),urinary albumin excretion rate(UAER),urinary microalbumin(mALB)]and thrombomodulin(TM),von Willefibrile factor(vWF),transforming growth factor-β1(TGF-β1)levels before and after treatment,and occurrence of adverse reactions between the two groups.Results After treatment,SBP and DBP levels in both groups were significantly lower than those before treatment;and SBP of(135.43±6.43)mm Hg(1 mm Hg=0.133 kPa)and DBP of(87.87±3.30)mm Hg in the observation group were significantly lower than(137.54±2.91)and(96.76±2.65)mm Hg in the control group(P<0.05).After treatment,the levels of CysC,Hcy,UAER and mALB in both groups were significantly lower than those before treatment;the observation group had CysC of(0.31±0.63)mg/L,Hcy of(6.14±0.34)μmol/L,UAER of(115.73±7.57)μg/min and mALB of(24.25±1.43)mg/L,which were significantly lower than(0.76±0.02)mg/L,(11.31±0.58)μmol/L,(127.38±5.49)μg/min and(35.36±0.81)mg/L in the control group(P<0.05).After treatment,the levels of TM,vWF and TGF-β1 in both groups were significantly lower than those before treatment;the observation group had TM of(27.32±0.99)mg/L,vWF of(115.37±6.11)%and TGF-β1 of(111.27±5.37)mg/ml,which were significantly lower than(39.43±1.26)mg/L,(132.43±5.39)%and(132.36±5.31)mg/ml in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between

关 键 词：糖尿病 高血压 硝苯地平控释片 福辛普利钠片 

分 类 号：R544.1[医药卫生—心血管疾病] R587.2[医药卫生—内科学]